Interviews

	Pushing the frontiers of disease prevention Wayne Pisano runs the largest company in the world devoted entirely to human vaccines. As CEO of sanofi pasteur, he knows more than most about the importance of vaccines as an essential tool in preventative healthcare. Here, he tells NGP about leading the worldwide fight against life-threatening infectious disease. More >>		A personalised approach Personalised medicines tailored to suit an individual’s genetic make-up could revolutionise the future of drug discovery. Frances Davies of NGP talks to Jan Lundberg of AstraZeneca about the revolutionary research needed to take advantage of this potential new direction. More >>
	Vaccines for the world Looking at the world’s vaccine market, GlaxoSmithKline is amongst the top players. The company’s vision is to challenge the world of vaccines with vaccines for the world. What’s the strategy behind the concept? Julia Puppe asked Jean Stéphenne, President of GSK Biologicals. More >>

Other Interviews

How to become a healthcare heavyweight
Bayer bought Schering in June 2006 with the intention to become a global healthcare heavyweight. As part of the integration process, the combined Bayer Schering pipeline has been evaluated and set for success.
More >>

Transformers
Pfizer is undergoing a transformation. Since the failure of its promising pill Torcetrapib all of Pfizer’s operating divisions have been closely examined to decide how they can help the company address the challenges ahead.
More >>

A silent epidemic
The prevalence of diabetes is increasing dramatically. To explore the economic cost of diabetes and examine some of the barriers that are preventing the diabetes epidemic from being more effectively addressed, Novo Nordisk supports an Economist Intelligence Unit report with an unrestricted educational grant.
More >>

Optimizing management of pharmaceutical-lab instruments
In recent years, pharmaceutical manufacturers have joined the long list of healthcare enterprises striving to reduce costs, without compromising quality.
More >>

The L-Factor: Executive insight: “We’ve got the critical mass”
Franz Humer, a lawyer by training, is CEO of F. Hoffmann-La Roche Ltd – a company whose strategy is to use innovative scientific breakthroughs to shape the future of medicine.
More >>

Biomark my words
Biomarkers are playing an increasingly important role in the development of new drugs to fight disease.
More >>

R&D: The NGP Head-to-Head
Research and development is the oxygen of modern pharmaceuticals – and there is a problem with supply.
More >>

Sales & Marketing: The NGP Head-to-Head
Branding is still a tricky issue for many in the pharma industry.
More >>

Executive Insight: the appliance of IT in science
NGP catches up with Geoff Odell, Chairman of the LSIT Global Institute and CIO of the Novartis Genomic Research Institute, to discover how instrumental IT is to the life science drug pipeline
More >>

A Pharma Carol
Jonathan Knowles on the ghosts of pharma past, present, and future
More >>

Risk management
David Mogg explains how regulatory compliance and Good Manufacturing Practices are helping pharma and biotech companies mitigate patient health risks. Interview by Louise Druce.
More >>

Is RFID pharma’s magic pill?
Bruce Hudson, Programme Director for Technology Research Services at META Group, says it?s not as simple as that ?¬ but does admit that ?we?re only now at the tip of the iceberg for what RFID is going to do.?
More >>